Literature DB >> 30275977

Identification of Burkholderia fungorum in the urine of an individual with spinal cord injury and augmentation cystoplasty using 16S sequencing: copathogen or innocent bystander?

Emma Nally1,2, Suzanne L Groah1,2, Marcos Pérez-Losada3,4,5, Ljubica Caldovic4, Inger Ljungberg1, Neel J Chandel6, Bruce Sprague7, Michael H Hsieh7, Hans G Pohl7.   

Abstract

INTRODUCTION: People with neuropathic bladder (NB) secondary to spinal cord injury (SCI) are at risk for multiple genitourinary complications, the most frequent of which is urinary tract infection (UTI). Despite the high frequency with which UTI occurs, our understanding of the role of urinary microbes in health and disease is limited. In this paper, we present the first prospective case study integrating symptom reporting, urinalysis, urine cultivation, and 16S ribosomal ribonucleic acid (rRNA) sequencing of the urine microbiome. CASE
PRESENTATION: A 55-year-old male with NB secondary to SCI contributed 12 urine samples over an 8-month period during asymptomatic, symptomatic, and postantibiotic periods. All bacteria identified on culture were present on 16S rRNA sequencing, however, 16S rRNA sequencing revealed the presence of bacteria not isolated on culture. In particular, Burkholderia fungorum was present in three samples during both asymptomatic and symptomatic periods. White blood cells of ≥5-10/high power field and leukocyte esterase ≥2 on urinalysis was associated with the presence of symptoms. DISCUSSION: In this patient, there was a predominance of pathogenic bacteria and a lack of putative probiotic bacteria during both symptomatic and asymptomatic states. Urinalysis-defined inflammatory markers were present to a greater extent during symptomatic periods compared to the asymptomatic state, which may underscore a role for urinalysis or other inflammatory markers in differentiating asymptomatic bacteriuria from UTI in patients with NB. The finding of potentially pathogenic bacteria identified by sequencing but not cultivation, suggests a need for greater understanding of the relationships amongst bacterial species in the bacteriuric neuropathic bladder.

Entities:  

Year:  2018        PMID: 30275977      PMCID: PMC6155001          DOI: 10.1038/s41394-018-0115-2

Source DB:  PubMed          Journal:  Spinal Cord Ser Cases        ISSN: 2058-6124


  24 in total

1.  Complications following spinal cord injury: occurrence and risk factors in a longitudinal study during and after inpatient rehabilitation.

Authors:  Janneke A Haisma; Lucas H van der Woude; Henk J Stam; Michael P Bergen; Tebbe A Sluis; Marcel W Post; Johannes B Bussmann
Journal:  J Rehabil Med       Date:  2007-05       Impact factor: 2.912

2.  Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury.

Authors:  A Esclarín De Ruz; E García Leoni; R Herruzo Cabrera
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

3.  Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer.

Authors:  Suzanne L Groah; David A Weitzenkamp; Daniel P Lammertse; Gale G Whiteneck; Dennis C Lezotte; Richard F Hamman
Journal:  Arch Phys Med Rehabil       Date:  2002-03       Impact factor: 3.966

4.  Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov.

Authors:  Tom Coenye; Johan Goris; Theodore Spilker; Peter Vandamme; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

5.  Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study.

Authors:  Y Chen; M J DeVivo; J M Roseman
Journal:  Spinal Cord       Date:  2000-06       Impact factor: 2.772

6.  Factors associated with survival after bladder cancer in spinal cord injury.

Authors:  Suzanne L Groah; Daniel P Lammertse
Journal:  J Spinal Cord Med       Date:  2003       Impact factor: 1.985

Review 7.  The etiology of urinary tract infection: traditional and emerging pathogens.

Authors:  Allan Ronald
Journal:  Am J Med       Date:  2002-07-08       Impact factor: 4.965

Review 8.  Urinary tract infection in the neurogenic bladder.

Authors:  Humberto R Vigil; Duane R Hickling
Journal:  Transl Androl Urol       Date:  2016-02

9.  Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury.

Authors:  Derrick E Fouts; Rembert Pieper; Sebastian Szpakowski; Hans Pohl; Susan Knoblach; Moo-Jin Suh; Shih-Ting Huang; Inger Ljungberg; Bruce M Sprague; Sarah K Lucas; Manolito Torralba; Karen E Nelson; Suzanne L Groah
Journal:  J Transl Med       Date:  2012-08-28       Impact factor: 5.531

Review 10.  Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders.

Authors:  Ryan D Heath; Courtney Cockerell; Ravinder Mankoo; Jamal A Ibdah; Veysel Tahan
Journal:  North Clin Istanb       Date:  2018-02-12
View more
  4 in total

1.  Spinal Cord Series and Cases: new regional focuses and updates.

Authors:  Marcalee Alexander
Journal:  Spinal Cord Ser Cases       Date:  2018-12-19

2.  Draft genome of Paraburkholderia fungorum sequence type 868 recovered from human synovial tissues.

Authors:  Shih Keng Loong; Kim-Kee Tan; Nurul-Izzani Zulkifle; Sazaly AbuBakar
Journal:  Data Brief       Date:  2019-06-20

3.  Genomic analyses of Burkholderia cenocepacia reveal multiple species with differential host-adaptation to plants and humans.

Authors:  Adrian Wallner; Eoghan King; Eddy L M Ngonkeu; Lionel Moulin; Gilles Béna
Journal:  BMC Genomics       Date:  2019-11-04       Impact factor: 3.969

4.  Comprehensive genome analysis of a pangolin-associated Paraburkholderia fungorum provides new insights into its secretion systems and virulence.

Authors:  Ka Yun Tan; Avirup Dutta; Tze King Tan; Ranjeev Hari; Rofina Y Othman; Siew Woh Choo
Journal:  PeerJ       Date:  2020-09-03       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.